90 results on '"Voloshin T"'
Search Results
2. Cancer cell permeability is increased after Tumor Treating Fields (TTFields) application
3. Application of Tumor Treating Fields (TTFields) to open the blood brain barrier (BBB) as future CNS drug delivery strategy
4. P-99 Tumor treating fields (TTFields) are effective for treatment of gastric cancer cells, boosting the activity of FOLFOX
5. PI3K Inhibition Sensitized Cancerous Cells to Tumor Treating Fields (TTFields)
6. Tumor Treating Fields (TTFields) Delivery to Macrophages Promotes a Pro-Inflammatory Phenotype
7. Enhancing Cancer Cell Membrane Permeability by Application of Tumor Treating Fields (TTFields)
8. EP16.03-028 Cancer Cells May be Re-sensitized to Tumor Treating Fields (TTFields) Through Inhibition of the PI3K/AKT/mTOR Pathway
9. EP16.01-016 Tumor Treating Fields (TTFields) Application Promotes a Pro-inflammatory Phenotype in Macrophages
10. P-121 Effects of tumor treating fields (TTFields) on gastric cancer cells and their potential concomitant application with FOLFOX
11. Mechanism of Action of Tumor Treating Fields (TTFields) in Combination with Sorafenib for Treatment of Hepatocellular Carcinoma
12. Impact of Tumor Treating Fields (TTFields) on DNA Damage Repair in Mesothelioma
13. Activated Phosphoinositide 3-Kinase/AKT/mTOR Signaling Confers Resistance to Tumor Treating Fields (TTFields)
14. FP07.04 Effect of Tumor Treating Fields (TTFields) on DNA Damage and The FA-BRCA DNA Repair Pathway in Mesothelioma
15. P-184 Underlining mechanism for the efficacy of tumor treating fields (TTFields) concomitant with sorafenib for treatment of hepatocellular carcinoma
16. P25.09 Effectiveness of Tumor Treating Fields plus Cisplatin/Pemetrexed Combination in Mesothelioma, in Vitro and in Vivo
17. P1.12-10 Sensitization of Cancer Cells to Tumor Treating Fields (TTFields) via Inhibition of the PI3K/AKT Signaling Pathway.
18. P-261 Safety and effectiveness of tumor treating fields combined with sorafenib in preclinical models of hepatocellular carcinoma
19. P-255 Effects of tumor treating fields (150 kHz) in combination with FOLFOX on gastric cancer cells in vitro
20. 1852P - Effects of tumor treating fields (TTFields; 150 kHz) and cisplatin or pemetrexed combination therapy on mesothelioma cells in vitro and in vivo
21. EP1.06-07 In Vivo Studies of Tumor Treating Fields to Upper Torso in Combination with Chemotherapy Show No Additional Toxicities
22. P1.06-17 Tumor Treating Fields (150 kHz) Combined with Cisplatin or Pemetrexed Inhibits Mesothelioma Cells in Vitro and in Vivo
23. Immunogenic Cell Death Induced by Tumor Treating Fields (TTFields) Enhances Efficacy When Combined with Anti-PD-1 Therapy in Lung and Colon Cancer Animal Models
24. The Combined Treatment of 150 kHz Tumor Treating Fields (TTFields) and FOLFOX Inhibit Gastric Cancer in Vitro
25. Efficacy of Tumor Treating Fields (TTFields) in Combination with Cisplatin or Pemetrexed for the Treatment of Mesothelioma in Vitro and in Vivo
26. Tumor Treating Fields (TTFields) Plus Sorafenib Is Safe and Effective in Hepatocellular Carcinoma Tested in Vitro and in an Animal Model
27. Animal Studies Evaluating the Safety of Tumor Treating Fields (TTFields) Alone and in Combination with Chemotherapy Agents Demonstrate No Additional Toxicities
28. Blood Brain Barrier (BBB) Integrity Is Affected By Tumor Treating Fields (TTFields) in Vitro and In Vivo
29. P-250 - The combined treatment of 150 kHz Tumor Treating Fields (TTFields) and sorafenib shows In vitro and in vivo efficacy in hepatocellular carcinoma
30. P-228 - Tumor Treating Fields (150 kHz) combined with FOLFOX inhibits gastric cancer in vitro
31. The Combined Treatment of 150 kHz Tumor Treating Fields (TTFields) and Cisplatin or Pemetrexed Inhibit Mesothelioma Cells In Vitro
32. Immunomodulatory Effect of Tumor Treating Fields (TTFields) Results in Enhanced Antitumor Efficacy When Combined with Anti-PD-1 Therapy in Mouse Model of Lung Cancer
33. Tumor Treating Fields (TTFields) Delay DNA Damage Repair Following Radiation Treatment of Glioma Cells: Implications for Irradiation Through TTFields Transducer Arrays
34. 1206P - Efficacy of tumor treating fields (TTFields) and anti-PD-1 in non-small-cell lung cancer (NSCLC) preclinical models
35. 39P - Efficacy of Tumor Treating Fields (TTFields) and anti-PD-1 in non-small cell lung cancer (NSCLC) preclinical models
36. Tumor Treating Fields (TTFields) Sensitize Glioma Tumor Cells to Radiation Therapy by Delaying DNA Damage Repair Through Homologous Recombination
37. Safety and Effectiveness of Tumor Treating Fields (TTFields; 150 kHz) and Sorafenib Combination Treatment in Hepatocellular Carcinoma In Vitro and In Vivo.
38. P04.55 Efficacy of Tumor Treating Fields (TTFields) and aurora B kinase inhibitor.
39. P04.16 Tumor treating fields affect invasion properties and cell morphology of various cancer cells.
40. P04.15 Autophagy induction following TTFields application serves as a survival mechanism mediated by AMPK signaling.
41. P02.04 Tumor treating fields induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy.
42. Effectiveness and Safety of Tumor Treating Fields (150 kHz) plus Cisplatin or Pemetrexed Combination in Mesothelioma: in Vitro and in Vivo Findings.
43. Correction: Davidi et al. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo . Cancers 2022, 14 , 2959.
44. Tumor Treating Fields (TTFields) Concomitant with Immune Checkpoint Inhibitors Are Therapeutically Effective in Non-Small Cell Lung Cancer (NSCLC) In Vivo Model.
45. Tumor Treating Fields (TTFields) Reversibly Permeabilize the Blood-Brain Barrier In Vitro and In Vivo.
46. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo .
47. Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models.
48. Tumor Treating Fields (TTFields) Hinder Cancer Cell Motility through Regulation of Microtubule and Acting Dynamics.
49. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy.
50. AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.